Filengia 0,5 mg Hard capsules.
PDF Leaflet Revision Date: 02 June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Disease modifying therapy for relapsing multiple sclerosis.
Dosage (summary)
1 capsule (0.5 mg) orally once daily, with or without food.
Onset of Action / Duration
Onset: 6 hours, Duration: Varies
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; effective contraception required.
Key Drug Interactions
- Beta blockers
- Calcium channel blockers
- Class Ia and III anti-dysrhythmics
Contraindications
- Hypersensitivity to fingolimod
- Recent myocardial infarction
- Severe hepatic impairment
- Pregnancy and lactation
- Known immunodeficiency syndrome
Common side effects
- Headache
- Influenza
- Diarrhoea
- Sinusitis
- Back pain
Counselling Points
- Monitor for signs of infection.
- Report any visual disturbances.
- Regular liver function tests recommended.
Serious warnings
- Bradycardia upon treatment initiation
- Risk of infections
- Potential for malignancies
Important Disclaimer
The Filengia 0,5 mg Hard capsules. professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
